Ramachandran Subramaniam, Faisal Thekkin Kattil, Anjumary Jose, Rajasekaran Aiyalu, Asokkumar Kuppusamy, Annadurai Kuppusamy, Arivukkarasu Ramasamy, Sharma Rajeev Kumar, Shankar Madhira Bhavani
.
J Complement Integr Med. 2017 Jun 22;14(3):/j/jcim.2017.14.issue-3/jcim-2016-0130/jcim-2016-0130.xml. doi: 10.1515/jcim-2016-0130.
Background Anogeissus latifolia Wall. (A. latifolia) bark has been traditionally used in the treatment of various diseases which includes diabetes and general debility. The present study was aimed to investigate the comparative hypoglycemic and hypolipidemic activity of various extracts of A. latifolia bark in streptozotocin-induced type 1 diabetic rats. Methods Acute toxicity was carried out at 2 g/kg dose of petroleum ether extract of A. latifolia bark (PEALB), chloroform extract of A. latifolia bark (CEALB) and methanol extract of A. latifolia bark (MEALB) in rats. Diabetes was induced by streptozotocin (STZ, 60 mg/kg, i.p.) and it was confirmed at 72 h. Diabetic rats received above extracts at 100 and 200 mg/kg doses for 28 days. Body weight and blood glucose level were determined at every week after the treatment schedule. Serum biochemical parameters and lipid profile levels were estimated at the end of the study. Results PEALB, CEALB and MEALB were non-toxic and no death was observed at 2 g/kg dose. Administration of MEALB at 100 and 200 mg/kg showed significant (p< 0.01, p< 0.05) improvement in body weight and reduction in blood glucose at third and fourth week of treatment. Altered serum biochemical parameters and lipid profiles level were brought to near normal level significantly (p<0.001) compared to diabetic control rats after the administration of both doses of MEALB. However, PEALB and CEALB did not exhibit significant hypoglycemic and hypolipidemic activity. Conclusions Our findings revealed that long-term (28 days) treatment of MEALB possesses significant hypoglycemic and hypolipidemic activity compared to PEALB and CEALB in type 1 diabetic rats and given evidence to the traditional use of A. latifolia bark in diabetes.
阔叶香须树(Anogeissus latifolia Wall.,A. latifolia)树皮传统上用于治疗包括糖尿病和全身虚弱在内的各种疾病。本研究旨在调查阔叶香须树树皮不同提取物对链脲佐菌素诱导的1型糖尿病大鼠的降血糖和降血脂活性比较。方法:以2 g/kg剂量的阔叶香须树树皮石油醚提取物(PEALB)、阔叶香须树树皮氯仿提取物(CEALB)和阔叶香须树树皮甲醇提取物(MEALB)对大鼠进行急性毒性试验。通过腹腔注射链脲佐菌素(STZ,60 mg/kg)诱导糖尿病,并在72小时后进行确认。糖尿病大鼠接受上述提取物100和200 mg/kg剂量,持续28天。治疗方案结束后每周测定体重和血糖水平。在研究结束时评估血清生化参数和血脂水平。结果:PEALB、CEALB和MEALB无毒,在2 g/kg剂量下未观察到死亡。给予100和200 mg/kg剂量的MEALB后,在治疗的第三和第四周体重显著增加(p<0.01,p<0.05),血糖降低。与糖尿病对照大鼠相比,给予两种剂量的MEALB后,血清生化参数和血脂水平的改变显著恢复到接近正常水平(p<0.001)。然而,PEALB和CEALB未表现出显著的降血糖和降血脂活性。结论:我们的研究结果表明,与PEALB和CEALB相比,长期(28天)给予MEALB对1型糖尿病大鼠具有显著的降血糖和降血脂活性,为阔叶香须树树皮在糖尿病治疗中的传统应用提供了证据。